Visomitin 0.155 mcg/ml SkQ1 bottle eye drops 5 ml MitoQ

They are used to correct initial age-related cataracts and dry eye syndrome. They have antioxidant and keratoprotective effects. Based on Skulachev ions – active compounds that protect the mitochondrial cell’s energy stations from oxidative stress.
Method of administration and dosage
Dry eye syndrome: 1-2 drops of the drug in the conjunctival sac 3 times a day. The duration of the course of treatment is determined by the doctor depending on the severity of the disease.
Initial stage of age-related cataract: 1-2 drops of the drug in the conjunctival sac 3 times a day. The duration of the course of treatment is 6 months. During therapy with the drug, it is necessary to monitor the ophthalmologist in order to assess the degree of progression of the disease and the need to continue conservative therapy.
Indications
-Dry eye syndrome.
-Initial stage of age-related cataract.
Composition
Composition per 1 ml:
Active substance:
Plastoquinonyldecyltriphenylphosphonium bromide (PDTP) 0.155 mcg
Excipients:
Benzalkonium chloride 0.1 mg, hypromellose 2 mg, sodium chloride 9 mg, sodium dihydrogen phosphate dihydrate 0.81 mg, sodium hydrogen phosphate dodecahydrate 1.16 mg, sodium hydroxide 1 M solution to pH 6.3 - 7.3, purified water to 1 ml.
Contraindications
Hypersensitivity to the components of the drug, age under 18 years.
PREGNANCY AND LACTATION
Adequate controlled studies in pregnant and lactating women have not been conducted. It is not recommended to prescribe the drug during pregnancy. If it is necessary to prescribe during lactation, breastfeeding should be discontinued for the period of treatment.
Special instructions
Effect on ability to drive vehicles and operate machinery
If short-term blurred vision occurs after using the drug, it is not recommended to drive vehicles or engage in activities that require increased concentration until it is restored.
Collapse
Packaging and release form
Eye drops with a concentration of 0.155 mcg/ml in 5 ml polyethylene bottles with dropper stoppers and screw caps. Each bottle with instructions for use is placed in a cardboard box.
Side effects
Allergic reactions.
Sensory organs: a short-term burning sensation and stinging in the eyes after instillation is possible.
INFORM YOUR DOCTOR ABOUT ANY ADVERSE REACTIONS OR SENSATIONS, INCLUDING THOSE NOT MENTIONED IN THESE INSTRUCTIONS, AS WELL AS ANY CHANGES IN LABORATORY INDICATORS DURING THERAPY.
Pharmacotherapeutic group
keratoprotective agent
Drug interactions
If necessary, it can be used simultaneously with other eye drops. In this case, the interval between instillations should be at least 5 minutes.
Pharmacodynamics
Plastoquinonyldecyltriphenylphosphonium bromide (PDTP) is a plastoquinone derivative, which is linked to a triphenylphosphine residue via a linker chain (C10). PDTP in low (nanomolar) concentrations exhibits high antioxidant activity. It also stimulates the process of tear production, epithelialization, and helps to increase the stability of the tear film.
One of the causes of age-related cataracts is the damaging effect of ultraviolet radiation, which initiates photooxidation processes leading to denaturation of the main structural component of the lens - crystallins. The first defense of eye tissues from ultraviolet radiation is the lacrimal fluid, which absorbs ultraviolet light in the range of 240-320 nm and neutralizes it due to the components of the antioxidant activity of the lacrimal fluid. According to preclinical studies, the anti-cataract effect of Vizomitin® is associated with an increase in the expression level of the main lens proteins - ?-crystallins, restoration of the lens epithelium and activation of energy processes in it. According to a clinical study, patients with age-related cataracts who used Vizomitin® showed an increase in the antioxidant activity of tears.

Storage temperature
from 2℃ to 8℃
Dosage form
Transparent or slightly opalescent, colorless or slightly colored liquid.
Pharmacokinetics
Pharmacokinetics studies in humans have not been conducted. In preclinical studies on animals, PDTF distribution in organs and tissues occurred within 48 hours after intravenous and intragastric administration. It was found that PDTF is present in the highest concentrations in the tissues of the kidney, liver and heart within 1 hour after administration. PDTF undergoes relatively rapid enzymatic cleavage and covalent binding to proteins.
Overdose
There are no data on overdose with local use.   MitoQ